Lumexa Imaging (NASDAQ:LMRI) Issues FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) updated its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.860-0.900 for the period, compared to the consensus earnings per share estimate of 0.660. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Lumexa Imaging in a research report on Tuesday, September 22nd. Barclays increased their price target on shares of Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a research report on Friday, August 28th. UBS Group reiterated a “strong-buy” rating on shares of Lumexa Imaging in a research note on Wednesday. Wall Street Zen upgraded Lumexa Imaging from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Finally, KeyCorp initiated coverage on Lumexa Imaging in a report on Thursday, September 24th. They issued an “overweight” rating and a $18.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $16.80.

Lumexa Imaging Trading Up 14.6%

Lumexa Imaging stock opened at $15.95 on Thursday. Lumexa Imaging has a 52-week low of $6.45 and a 52-week high of $19.45. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 1.40. The firm has a market capitalization of $1.53 billion and a price-to-earnings ratio of -29.54. The firm has a 50-day moving average price of $11.33 and a two-hundred day moving average price of $11.08.

Lumexa Imaging (NASDAQ:LMRI) last issued its quarterly earnings data on Tuesday, November 10th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.19. Lumexa Imaging had a negative net margin of 1.96% and a negative return on equity of 2.93%. The business had revenue of $271.97 million for the quarter. Sell-side analysts expect that Lumexa Imaging will post 0.25 earnings per share for the current year.

Key Headlines Impacting Lumexa Imaging

Here are a few of the latest headlines about LMRI:

• Positive Sentiment: Coverage pointed to higher advanced-imaging volumes helping the company return to profitability, while lower interest costs also supported earnings. Article: Advanced imaging volumes support profitability
• Positive Sentiment: Adjusted quarterly EPS was reported at $0.26, above the $0.07 consensus cited in earnings coverage. Operating cash flow also rose sharply year over year to $34.8 million. Article: Q3 earnings and interest costs
• Negative Sentiment: Operating profit declined 7.3% year over year, and net income attributable to common shareholders was $7.2 million. The company also reported $1.2 billion in total liabilities, which may temper optimism about the earnings outlook. Article: Third-quarter results

Lumexa Imaging Company Profile

Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.